Cargando…
Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody
Daratumumab is a monoclonal immunoglobulin against CD38 and has been approved for treating patients with refractory multiple myeloma. The presence of daratumumab in the sera can interfere with pretransfusion testing due to the weakly expression of CD38 on red cells. The reactivity could be mistaken...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613434/ https://www.ncbi.nlm.nih.gov/pubmed/28970695 http://dx.doi.org/10.4103/0973-6247.214358 |